/EINPresswire.com/ -- PALATINE, IL--(Marketwired - April 21, 2016) - Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the Company plans to report financial results for the first quarter 2016 following the close of financial markets on Monday, May 2, 2016. The Company will host a conference call to discuss the results on Tuesday, May 3, 2016 at 8:30 a.m. ET.

To participate in the live conference call, please dial 888-339-3513 (U.S. and Canada) five to ten minutes prior to the start of the call. The participant passcode is 6043967.

A replay of the call will be available beginning May 3, 2016 and ending on May 24, 2016 on the company's website, and by dialing 888-203-1112 (U.S. and Canada). The replay participant code is 6043967.

About Acura Pharmaceuticals
Acura Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development and commercialization of product candidates intended to address medication abuse and misuse, utilizing its proprietary LIMITX™, AVERSION® and IMPEDE® Technologies. LIMITX contains ingredients that are intended to reduce or limit the rate or extent of opioid release when multiple tablets are ingested. AVERSION contains polymers that cause the drug to gel when dissolved; it also contains compounds that irritate the nasal passages if the product is snorted. IMPEDE is designed to disrupt the processing of pseudoephedrine from tablets into methamphetamine.

OXAYDO® (oxycodone HCl immediate-release tablets) which incorporates the AVERSION Technology, is FDA approved and marketed in the U.S. by our partner Egalet Corporation. 

Acura markets NEXAFED® and NEXAFED® Sinus, which are pseudoephedrine containing products that utilize the IMPEDE Technology.

Contact:
for Acura Investor Relations
Email contact

847-705-7709

Renmark Financial Communications Inc.
Robert Thaemlitz
Email contact

(416) 644-2020 or (514) 939-3989
www.renmarkfinancial.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.